Mobile App

Google Play Apple Store

Updates in High-Risk Myelodysplastic Syndromes (MDS) - Conversation 1 of 2
Certified AMA/ANCC/ACPE Activity
High-risk myelodysplastic syndromes (MDS) pose a challenge in terms of diagnosis, risk stratification, and treatment. Additionally, in recent years, the clinical, molecular, cellular, and immunological factors associated with high-risk MDS have become clearer.

This has led to several updates in the diagnosis and management of high-risk MDS, which will be discussed by Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji. The expert faculty will also review clinical case scenarios to guide participants in integrating recent updates in high-risk MDS.
Review this activity and claim AMA or ANCC credit/contact hour(s) after completion of the post-test / evaluation.


 Courtney DiNardo, MD, MSCE Courtney DiNardo, MD, MSCE
Associate Professor
UT MD Anderson Cancer Center
 Rami Komrokji, MD Rami Komrokji, MD
Section Head - Leukemia & MDS, Vice Chair Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
Morsani College of Medicine, University of South Florida
Gail Roboz, MD Gail Roboz, MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Cornell Medicine
The New York Presbyterian Hospital

Supported by independent educational grants from Genentech, Novartis, Taiho and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Launch Date: November 22, 2021
Release Date: November 18, 2021
Expiration Date: September 30, 2022

September 30, 2022
Mini Module


Change Settings